INmune Bio Inc. - Common stock (INMB) News
Filter INMB News Items
INMB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INMB News Highlights
- For INMB, its 30 day story count is now at 2.
- Over the past 19 days, the trend for INMB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about INMB are BIO and NOV.
Latest INMB News From Around the Web
Below are the latest news stories about INMUNE BIO INC that investors may wish to consider to help them evaluate INMB as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! |
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDAEnrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial. In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023. Boca R |
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer SymposiumINB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the tumor killing immunology of the tumor microenvironment. Boca Raton, Florida, Nov. 29, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is prese |
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s DiseaseBoca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the patient’s innate immune system to combat disease, announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spa |
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just BeginningBiogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started. |
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in EuropeThe Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon. The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive. Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing trea |
7 Earnings Losers to Load Up On Right NowGenerally speaking, earnings losers represent exactly that – companies that failed to deliver against established targets. |
INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call TranscriptINmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript November 1, 2023 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.00048, expectations were $-0.39. Operator: Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal […] |
Q3 2023 INmune Bio Inc Earnings CallQ3 2023 INmune Bio Inc Earnings Call |
INmune Bio Inc (INMB) Reports Q3 2023 Financial ResultsCompany's Cash and Cash Equivalents Decrease by 19.8% from the Previous Year |